Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03901092 · ClinicalTrials.gov registry record · Phase 3
A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation
A Phase 3 study of Alzheimer Disease, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
- 1
- Study location
NCT03901092: Completed Phase 3 study of Alzheimer Disease, sponsored by Avid Radiopharmaceuticals.
NCT03901092 is a Phase 3 study of Alzheimer Disease that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 242 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03901092, a Phase 3 study of Alzheimer Disease, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the performance of physician readers trained to read flortaucipir-PET (positron emission tomography) scans.
Primary Outcome
Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem 18F-AV-1451 PET imaging for detection of a pattern of 18F-AV-1451 neocortical uptake that corresponds to neurofibrillary tangles (NFT) Score of B3 (Hyman et al., 2012; Montine et al., 2012). NFT B scores range from B0 (no NFTs in the brain) to B3 (widespread NFTs in the brain). Sensitivity and specificity are percentages that can range from 0 to 100%. The hypothesis tested was that, of the 5 independent imaging
Conditions Studied
Interventions
- DRUG flortaucipir F 18
Study Locations (1)
Pennsylvania
- American College of Radiology - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2019-04-26 |
| Phase | Phase 3 |
What the finished NCT03901092 record still lists
NCT03901092 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which flortaucipir F 18 is the first listed.
NCT03901092 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03901092 about?
NCT03901092 is a clinical study titled "A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation". This study will evaluate the performance of physician readers trained to read flortaucipir-PET (positron emission tomography) scans.
What is the current status of trial NCT03901092?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2019-03-26. Estimated completion is 2019-04-26.
What conditions does trial NCT03901092 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT03901092?
The interventions under investigation include: flortaucipir F 18 (DRUG).
Who is sponsoring clinical trial NCT03901092?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03901092 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03901092's enrollment target sits among peer trials
242 93rd of 306 higher than 214 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Biomarker Exploration in Aging, Cognition and Neurodegeneration
RECRUITING · Phase 3
-
Epidemiology and Biomarker Study in Alzheimer's Disease
RECRUITING · Phase 3
-
[18F]PI-2620 Phase 3 Histopathological Study
RECRUITING · Phase 3
-
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
RECRUITING · Phase 3
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI